Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome

International Journal of Dermatology

Volumn 48, Issue 2, 2009, Pages 162-169

  Sehgal, Virendra N ^a,b,c   Srivastava, Govind ^a,b  

^a Sehgal Nursing Home   (India)

^b Skin Institute and School of Dermatology   (India)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ARTICLE; AUTOIMMUNE DISEASE; BLISTER; BLOOD DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; INCIDENCE; ORAL BIOPSY; PAPULE; PARANEOPLASTIC PEMPHIGUS; PLASMAPHERESIS; SKIN DEFECT; UNSPECIFIED SIDE EFFECT;

HUMANS; MULTIPLE ORGAN FAILURE; PARANEOPLASTIC SYNDROMES; PEMPHIGUS;

EID: 59149089698     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03995.x     Document Type: Article

References (131)

1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-1735.
2. Camisa C, Helm TN, Liu YC, et al. Paraneoplastic pemphigus: A report of three cases including one long-term survivor. J Am Acad Dermatol 1992; 27: 547-553.
3. Mutasim DF, Pelc NJ, Anhalt GJ. Pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus. Clin Dermatol 1993; 11: 113-117.
4. Berg WA, Fishman EK, Anhalt GJ. Retroperitoneal reticulum cell sarcoma: a cause of paraneoplastic pemphigus. South Med J 1993; 86: 215-217.
5. Rybojad M, Leblanc T, Flageul B, et al. Paraneoplastic pemphigus in a child with a T-cell lymphoblastic lymphoma. Br J Dermatol 1993; 128: 418-422.
6. Patten SF, Dijkstra JW. Associations of pemphigus and autoimmune disease with malignancy or thymoma. Int J Dermatol 1994; 33: 836-842.
7. Fried R, Lynfield Y, Vitale P, et al. Paraneoplastic pemphigus appearing as bullous pemphigoid-like eruption after palliative radiation therapy. J Am Acad Dermatol 1993; 29: 815-817.
8. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology 1995; 190: 245-250.
9. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995; 132: 474-478.
10. Chorzelski T, Hashimoto T, Maciejewska B, et al. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol 1999; 41: 393-400.
11. Sherer Y, Shoenfeld Y. A malignancy work-up in patients with cancer-associated (paraneoplastic) autoimmune diseases: Pemphigus and myasthenic syndromes as cases in point. Oncol Rep 1999; 6: 665-668.
12. Bowman PH, Hogan DJ. Pemphigus foliaceus and renal cell carcinoma. Cutis 1999; 63: 271-274.
13. Hertzberg MS, Schifter M, Sullivan J, et al. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: Significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63: 105-106.
14. Mahoney MG, Aho S, Uitto J, et al. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998; 111: 308-313.
15. Kiyokawa C. Envoplakin and periplakin are the paraneoplastic pemphigus antigens. Kurume Med J 1999; 46: 71-78.
16. Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269-272.
17. Ohyama M, Amagai M, Hashimoto T, et al. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol 2001; 44: 593-598.
18. Ishil M, Izumi J, Fujiwara H, et al. Immunoblotting detection of gamma-catenin (plakoglobin) antibody in the serum of a patient with paraneoplastic pemphigus. Br J Dermatol 2001; 144: 377-379.
19. Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001;137: 193-206.
20. Mehregan DR, Oursler JR, Leiferman KM, et al. Paraneoplastic pemphigus: a subset of patients with pemphigus and neoplasia. J Cutan Pathol 1993; 20: 203-210.
21. Thivolet J. Pemphigus: Past, present and future. Dermatology 1994; 189: 26-29.
22. Hasimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res 2003; 295: 2-11.
23. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129: 883-886.
24. Helm TN, Camisa C, Valenzuela R, et al. Paraneoplastic pemphigus. A distinct autoimmune vesiculobullous disorder associated with neoplasia. Oral Surg Oral Med Oral Pathol 1993; 75: 209-213.
25. Heymann WR. Paraneoplastic autoimmune multiorgan syndrome. J Am Acad Dermatol 2004; 51: 631-632.
26. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12: 77-96.
27. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin 1993; 11: 473-481.
28. Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc 2004; 9: 29-33.
29. Anhalt GJ. Paraneoplastic pemphigus. the role of tumours and drugs. Br J Dermatol 2001; 144: 1102-1104.
30. Younus J, Ahmed AR. The relationship of pemphigus to neoplasia. J Am Acad Dermatol 1990; 23: 498-502.
31. Ogawa H, Sakuma M, Morioka S, et al. The incidence of external malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9: 135-141.
32. Gibson LE, Muller SA. Dermatologic disorders in patients with thymoma. Acta Derm Venereol 1987; 67: 351-356.
33. Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147: 725-732.
34. Mar WA, Glaesser R, Struble K, et al. Paraneoplastic pemphigus with bronchiolitis obliterans in a child. Pediatr Dermatol 2003; 20: 238-242.
35. Lane JE, Woody C, Davis LS, et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: Case report and review of the literature. Pediatrics 2004; 114: 513-516.
36. Sklavounou A, Laskaris G. Paraneoplastic pemphigus: A review. Oral Oncol 1998; 34: 437-440.
37. Wade MS, Black MM. Paraneoplastic pemphigus: A brief update. Australas J Dermatol 2005; 46: 1-8.
38. Bazarbachi A, Bachelez H, Dehen L, et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann Oncol 1995; 6: 730-731.
39. Lee MS, Kossard S, Ho KK, et al. Paraneoplastic pemphigus triggered by radiotherapy. Australas J Dermatol 1995; 36: 206-210.
40. Ostezan LB, Fabre VC, Caughman SW, et al. Paraneoplastic pemphigus in the absence of a known neoplasm. J Am Acad Dermatol 1995; 33: 312-315.
41. Schlesinger T, McCarron K, Camisa C, et al. Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin's lymphoma. Cutis 1998; 61: 94-96.
42. Mahler V, Antoni C, Anhalt GJ, et al. Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphoma. Dermatology 1998; 197: 78-83.
43. Stark GL, Goff DK, Spickett GP, et al. Paraneoplastic pemphigus occurring after radiotherapy for relapsed non-Hodgkin's lymphoma in a patient with common variable immunodeficiency. Hematol J 2003; 4: 154-158.
44. Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: A review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 553-562.
45. Marzano AV, Grammatica A, Cozzani E, et al. Paraneoplastic pemphigus. A report of two cases associated with chronic B-cell lymphocytic leukaemia. Br J Dermatol 2001; 145: 127-131.
46. Bronnimann M, von Felbert V, Streit M, et al. Progressive respiratory failure in paraneoplastic pemphigus associated with chronic lymphocytic leukemia. Dermatology 2004; 208: 251-254.
47. VanMook WNK, Fickers MM, Theunissen PH, et al. Paraneoplastic pemphigus as the initial presentation of chronic lymphocytic leukemia. Ann Oncol 2001; 12: 115-118.
48. Pizarro A, Garcia-Tobaruela A, Pinilla J. Bronchiolitis obliterans, Castleman's disease (3), and a bullous disease: Pemphigus vulgaris or paraneoplastic pemphigus? Hum Pathol 1998; 29: 657-658.
49. Leyn J, Degreef H. Paraneoplastic pemphigus in a patient with a thymoma. Dermatology 2001; 202: 151-154.
50. Hartz RS, Daroca PJ. Clinical-pathologic conference: Cutaneous paraneoplastic pemphigus associated with benign encapsulated thymoma. J Thorac Cardiovasc Surg 2003; 125: 400-446.
51. Parera GK, Deverex S, Creamer D, et.al. PNP with Waldenstrom's macroglobulinemia. Clin Exp Dermatol 2005; 30: 27-29.
52. Dega H, Laporte JL, Joly P, et.al. Paraneoplastic pemphigus associated with Hodgkin's disease. Br J Dermatol 1998; 138: 196-198.
53. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43: 619-626.
54. Fullerton SH, Woodley DT, Smoller BR, et al. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. J Am Med Assoc 1992; 267: 1500-1502.
55. Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis in paraneoplastic pemphigus: A pathogenic trigger of epitope spreading? Arch Dermatol 2000; 136: 652-656.
56. Martel P, Gilbert D, Labeille B et al. A case of paraneoplastic pemphigus with antidesmoglein 1 antibodies as determined by immunoblotting. Br J Dermatol 2000; 142: 812-813.
57. Inaoki M, Kodera M, Fujimoto A et al. Paraneoplastic pemphigus without antidesmoglein 3 or antidesmoglein autoantibodies. Br J Dermatol 2001; 144: 610-613.
58. Matz H, Milner Y, Frusic-Zlotkin M, et al. Paraneoplastic pemphigus associated with pancreatic carcinoma. Acta Derm Venereol 1997; 77: 289-291.
59. Wong KC, Ho KK. Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 2000; 41: 178-180.
60. Schoen H, Foedinger D, Derfler K, et al. Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 1998; 134: 706-710.
61. Lee IJ, Kim SC, Kim HS, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman's tumor. J Am Acad Dermatol 1999; 40: 294-297.
62. Qurster JR, Labib RS, Ariss-Abdo L, et al. Human antibodies against desmoplakins in PNP. J Clin Invest 1992; 89: 1775-1782.
63. VanderWall RI, Pas HH, Anhalt GJ, et al. PNP as the presenting symptom of lymphoma of the tongue. Oral Oncol 1998; 34: 567-570.
64. Schaeppi H, Bauer JW, Hametner R, et al. Localized variant of paraneoplastic pemphigus: Acantholysis associated with malignant melanoma. Br J Dermatol 2001; 144: 1249-1254.
65. Lemon MA, Weston WL, Huff JC. Childhood paraneoplastic pemphigus associated with Castleman's tumour. Br J Dermatol 1997; 136: 115-117.
66. Chin AC, Stich D, White FV, et al. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: A rare case of Castleman's disease with respiratory failure requiring lung transplantation. J Pediatr Surg 2001; 36: 22.
67. Cordel N, Ringeisen F, Antoine M, et al. Paraneoplastic pemphigus with constrictive bronchiolitis obliterans. Dermatology 2001; 202: 145.
68. Hasegawa Y, Shimokata K, Ichiyama S, et al. Constrictive bronchiolitis obliterans and paraneoplastic pemphigus. Eur Respir J 1999; 13: 934-937.
69. Preisz K, Horvath A, Sardy M, et al. Exacerbation of paraneoplastic pemphigus by cyclophosphamide treatment: Detection of novel auto-antigens and bronchial autoantibodies. Br J Dermatol 2004; 150: 1018-1024.
70. Gooptu C, Littlewood TJ, Frith P, et al. Paraneoplastic pemphigus: An association with fludarabine? Br J Dermatol 2001; 144: 1255-1261.
71. Powell AM, Albert S, Oyama N, et al. Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans. J Eur Acad Dermatol Venereol 2004; 18: 360-364.
72. Lyon CC, Carmichael AJ. Toxic epidermal necrolysis and paraneoplastic pemphigus. Lancet 1998; 352: 149.
73. Ng PP, Ng SK, Chng HH. Pemphigus foliaceus and oral lichen planus in a patient with systemic lupus erythematosus and thymoma. Clin Exp Dermatol 1998; 23: 181-184.
74. Mascaro JM Jr, Ferrando J, Sole MT, et al. Paraneoplastic pemphigus: A case of long-term survival associated with systemic lupus erythematosus and polymyositis. Dermatology 1999; 199: 63-66.
75. Korang K, Ghohestani R, Krieg T, et al. Exacerbation of pemphigus foliaceus after tetanus vaccination accompanied by synthesis of auto-antibodies against paraneoplastic pemphigus antigens. Acta Derm Venereol 2002; 82: 482-483.
76. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128: 1091-1095.
77. Liu AY, Valenzuela R, Helm TN, et al. Indirect immunofluorescence on rat bladder transitional epithelium: A test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol 1993; 28: 696-699.
78. Moll R, Moll I. Epidermal adhesion molecules and basement membrane components as target structures of autoimmunity. Virchows Arch 1998; 432: 487-504.
79. Nagata Y, Karashima T, Watt FM, et al. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol 2001; 116: 556-563.
80. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32: 441-447.
81. Anhalt GJ. Making sense of antigens and antibodies in pemphigus. J Am Acad Dermatol 1999; 40: 763-766.
82. Futei Y, Amagai M, Hashimoto T, et al. Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol 2003; 49: 1023-1028.
83. Wang L, Bu D, Yang Y, et al. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004; 14: 525-531.
84. Seishima M, Oda M, Oyama Z, et al. Antibody titers to desmogleins 1 and 3 in a patient with paraneoplastic pemphigus associated with follicular dendritic cell sarcoma. Arch Dermatol 2004; 140: 1500-1503.
85. Aho S, Mahoney MG, Uitto J. Plectin serves as an auto-antigen in paraneoplastic pemphigus. J Invest Dermatol 1999; 113: 422-423.
86. Chan LS. Epitope spreading in paraneoplastic pemphigus: Autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol 2000; 136: 663-664.
87. Chiewchanvit S, Hashimoto T, Chaiwun B, et al. A pemphigus case with long term survival, implicating the spectrum between paraneoplastic pemphigus and pemphigus vulgaris. Int J Dermatol 1997; 36: 957-958.
88. Martel P, Loiseau P, Joly P, et al. PNP associated with the DRB1-03 allele. J Autoimmune 2003; 20: 91-95.
89. Hashimoto T. Immunopathology of paraneoplastic pemphigus. Clin Dermatol 2001; 19: 675-682.
90. de Bruin A, Muller E, Wyder M, et al. Periplakin and envoplakin are target antigens in canine and human paraneoplastic pemphigus. J Am Acad Dermatol 1999; 40: 763-766.
91. Nousari HC, Kimyai-Asadi A, Anhalt GJ, et al. Elevated serum levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol 1999; 112: 396-398.
92. Kiyokawa C, Ruhrberg C, Nie Z, et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol 1998; 111: 1236-1238.
93. Proby C, Fujii Y, Owaribe K, et al. Human autoantibodies against HD1/ plectin in paraneoplastic pemphigus. J Invest Dermatol 1999; 112: 153-156.
94. Aessopos A, Grapsa A, Farmakis D et al. Oral paraneoplastic pemphigus associated with renal malignancy. Acta Derm Venereol 2003; 83: 72-73.
95. Osmanski JP 2nd, Fraire AE, Schaefer OP. Necrotizing tracheobronchitis with progressive airflow obstruction associated with paraneoplastic pemphigus. Chest 1997; 112: 1704-1707.
96. Passeron T, Bahadoran P, Lacour JP, et al. Paraneoplastic pemphigus presenting as erosive lichen planus. Br J Dermatol 1999; 140: 552-553.
97. Meyers SJ, Varley GA, Meisler DM, et al. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol 1992; 114: 621-624.
98. Bialy-Golan A, Brenner S, Anhalt GJ. Paraneoplastic pemphigus: Oral involvement as the sole manifestation. Acta Derm Venereol 1996; 76: 253-254.
99. Nishibori Y, Hashimoto T, Ishiko A, et al. Paraneoplastic pemphigus: The first case report from Japan. Dermatology 1995; 191: 39-42.
100. Herrada J, Phillips DK, Hebert AA, et al. A progressive blistering eruption in a patient with lymphoma. Paraneoplastic pemphigus. Arch Dermatol 1997; 133: 97, 100-101.
101. Ahmed AR, Avram MM, Duncan LM. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. Case records of the Massachusetts General Hospital. Weekly clinico-pathological exercises. Case 23-2003. N Engl J Med 2003; 24: 382-391.
102. Ng PP, Rencic A, Nousari HC. Paraneoplastic pemphigus: A refractory autoimmune mucocutaneous disease. J Cutan Med Surg 2002; 6: 434-437.
103. Stevens SR, Griffiths CE, Anhalt GJ, et al. Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol 1993; 129: 866-869.
104. Nousari HC, Moresi M, Klapper M, et al. Non-endemic pemphigus foliaceus presenting as fatal bullous exfoliative erythroderma. Cutis 2001; 67: 251-252.
105. Goon AT, Tan SH. Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore. Australas J Dermatol 2001; 42: 172-175.
106. Abreu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003; 49: 599-608.
107. Tankel M, Tannenbaum S, Parekh S. Paraneoplastic pemphigus presenting as an unusual bullous eruption. J Am Acad Dermatol 1993; 29: 825-828.
108. Sapadin AN, Anhalt GJ. Paraneoplastic pemphigus with a pemphigus vegetans-like plaque as the only cutaneous manifestation. J Am Acad Dermatol 1998; 39: 867-871.
109. Chorzelski TP, Hashimoto T, Amagai M, et al. Paraneoplastic pemphigus with cutaneous and serological features of pemphigus foliaceus. Br J Dermatol 1999; 141: 357-359.
110. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667-672.
111. Izaki S, Yoshizawa Y, Hashimoto T, et al. Paraneoplastic pemphigus: report of a case. J Dermatol 1996; 23: 397-404.
112. Favia GF, Di Alberti L, Piattelli A. Paraneoplastic pemphigus: A report of two cases. Oral Oncol 1998; 34: 571-575.
113. Coelho S, Reis JP, Tellechea O, et al. Paraneoplastic pemphigus with clinical features of lichen planus associated with low-grade B cell lymphoma. Int J Dermatol 2005; 44: 366-371.
114. Hinterhuber G, Drach J, Riedl E et al. Paraneoplastic pemphigus in association with hepatocellular carcinoma. J Am Acad Dermatol 2003; 49: 538-540.
115. Garcia-Rio F, Alvarez-Sala R, Pino JM. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340: 6-10.
116. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340: 1406-1410.
117. Loo WJ, Burrows NP. Management of autoimmune skin disorders in the elderly. Drugs Aging 2004; 21: 767-777.
118. Grando SA. New approaches to the treatment of pemphigus. J Invest Dermatol Symp Proc 2004; 9: 84-91.
119. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1065-1069.
120. Gergely L, Varoczy L, Vadasz G, et al. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 2003; 109: 202-205.
121. Schadlow MB, Anhalt GJ, Sinha A. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564-567.
122. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66: 142-144.
123. Nousari HC, Brodsky RA, Jones RJ, et al. Immuno-ablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999; 40: 750-754.
124. Cohen MA, Cohen JJ, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in pemphigus foliaceus. Int J Dermatol 2002; 41: 340-344.
125. Becker LR, Bastian BC, Wesselmann U, et al. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol 1998; 8: 551-553.
126. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003; 149: 138-145.
127. Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-508.
128. Hohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 2004; 73: 206-209.
129. Vechietti G, Kerl K, Hugli A, et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br J Dermatol 2003; 148: 833-834.
130. Izaki S, Yoshizawa Y, Kitamura K, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol 1996; 134: 987-989.
131. Vun YY, Lun K, Strutton G. Use of biosynthetic dressings in paraneoplastic pemphigus. Australas J Dermatol 2004; 45: 133-135.